| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at TransCode Therapeutics, Inc. have bought $0 and sold $0 worth of TransCode Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at TransCode Therapeutics, Inc. have bought $88,712 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 98,000 shares for transaction amount of $49,980 was made by Dudley Robert Michael (Chief Executive Officer) on 2023‑09‑28.
| 2023-09-28 | Dudley Robert Michael | Chief Executive Officer | 98,000 4.2888% | $0.51 | $49,980 | -96.46% | ||
| 2023-09-28 | Fitzgerald Thomas A | Chief Financial Officer | 49,350 2.1597% | $0.51 | $25,169 | -96.46% | ||
| 2023-06-21 | Dudley Robert Michael | Chief Executive Officer | 12,000 0.0815% | $2.65 | $31,818 | -93.94% | ||
| 2023-06-20 | Dudley Robert Michael | Chief Executive Officer | 6,607 0.0443% | $2.55 | $16,847 | -93.73% | ||
| 2023-06-09 | Dudley Robert Michael | Chief Executive Officer | 19,000 0.131% | $2.76 | $52,440 | -93.23% | ||
| 2022-09-14 | Dudley Robert Michael | Chief Executive Officer | 20,000 0.1541% | $1.15 | $23,000 | -73.09% | ||
| 2022-06-16 | Fitzgerald Thomas A | Chief Financial Officer | 12,000 0.0932% | $1.27 | $15,240 | -63.79% | ||
| 2022-05-27 | Dudley Robert Michael | Chief Executive Officer | 28,000 0.2175% | $1.84 | $51,643 | -73.35% |
| Increased Positions | 2 | +20% | 3,709 | +25.7% |
| Decreased Positions | 3 | -30% | 14,263 | -98.82% |
| New Positions | <1 | New | 2,964 | New |
| Sold Out Positions | 3 | Sold Out | 14,263 | Sold Out |
| Total Postitions | 9 | -10% | 3,880 | -73.12% |
| Drw Securities, Llc | $87.00 | 1.17% | 11,702 | +11,702 | New | 2025-09-30 |
| Citigroup Inc | $12.00 | 0.16% | 1,586 | +1,586 | New | 2025-09-30 |
| Federation Des Caisses Desjardins Du Quebec | $7.00 | 0.1% | 975 | +975 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.01% | 142 | -260 | -64.68% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 10 | 0 | 0% | 2025-09-30 |
| Royal Bank Of Canada | $0 | <0.01% | 8 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | <0.01% | 8 | 0 | 0% | 2025-09-30 |
| Osaic Holdings, Inc. | $0 | 0% | 3 | 0 | 0% | 2025-09-30 |
| Fmr Llc | $0 | 0% | 0 | -3 | Sold Out | 2025-09-30 |
| Goldman Sachs Group Inc | $0 | 0% | 0 | -28,042 | Sold Out | 2025-09-30 |